

[Submitting Counsel on Signature Page]

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION

IN RE JUUL LABS, INC.,
MARKETING, SALES PRACTICES,
AND PRODUCTS LIABILITY
LITIGATION

Case No. 19-md-02913-WHO

TRIAL TESTIMONY AND EXHIBITS
FROM THE VIDEOTAPED TESTIMONY
OF JOSE MURILLO PLAYED AT TRIAL

This Document Relates to:

*San Francisco Unified School District v.
Juul Labs, Inc. et al., Case No. 3:19-cv-
08177*

Plaintiff, by and through its undersigned attorneys, hereby doctests the following:

1. **Exhibit 1** is a report of the videotaped testimony of Jose Murillo that was played to the jury on May 4, 2023. The testimony in blue 00:11:02 and light blue 00:02:33 Plaintiff's affirmative and counter-counter designations.
2. **Exhibit 2**: is a *Joint Stipulation Identifying Trial Exhibits Used In Videotaped Depositions of Jose Murillo Played at Trial* that sets forth all of the Trial Exhibits from the videotaped testimony of Jose Murillo admitted into evidence by the Court.

1 Respectfully submitted,

2 By: /s/ *Michael M. Weinkowitz*

3 Michael M. Weinkowitz

4 **LEVIN SEDRAN & BERMAN, LLP**

5 510 Walnut Street

6 Suite 500

7 Philadelphia PA 19106

Telephone 215-592-1500

MWeinkowitz@lfsblaw.com

8 Plaintiff Steering Committee Member

9 *Sarah R. London*

10 Sarah R. London

11 **LIEFF CABRASER HEIMANN & BERNSTEIN**

12 275 Battery Street, Fl. 29

13 San Francisco, CA 94111

14 Telephone: (415) 956-1000

slondon@lchb.com

15 By: /s/ *Dena C. Sharp*

16 Dena C. Sharp

17 **GIRARD SHARP LLP**

18 601 California St., Suite 1400

19 San Francisco, CA 94108

20 Telephone: (415) 981-4800

dsharp@girardsharp.com

21 By: /s/ *Dean Kawamoto*

22 Dean Kawamoto

23 **KELLER ROHRBACK L.L.P.**

24 1201 Third Ave., Ste. 3200

25 Seattle, WA 98101

26 Telephone: (206) 623-1900

27 By: /s/ *Ellen Relkin*

28 Ellen Relkin

WEITZ & LUXENBERG

700 Broadway

New York, NY 10003

Telephone: (212) 558-5500

Co-Lead Counsel for Plaintiff

EXHIBIT 1

MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

Designation List Report



Murillo, Jose
Murillo, Jose

2021-10-20
2021-10-21

| | |
|-----------------------|-----------------|
| PLF AFFIRMATIVE | 00:11:02 |
| DEF COUNTER | 00:06:10 |
| PLF COUNTER-COUNTER | 00:02:33 |
| TOTAL RUN TIME | 00:19:46 |



Documents linked to video:

MURILLO50019
MURILLO50020

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|---------------|--|----------|--------|
| 12:15 - 12:18 | Murillo, Jose 2021-10-20_WIT | 00:00:06 | MJv6.1 |
| | 12:15 Q. Sir, can you please tell us 12:16 your name? 12:17 A. My full name is Jose Luis 12:18 Murillo. | | |
| 14:03 - 14:16 | Murillo, Jose 2021-10-20_WIT | 00:00:27 | MJv6.2 |
| | 14:03 Q. And, sir, you're currently 14:04 employed by JUUL Labs Inc., right? 14:05 A. Correct. 14:06 Q. And what is your current 14:07 position? 14:08 A. Chief regulatory officer. 14:09 Q. Is there anyone above you in 14:10 the regulatory world at JUUL? 14:11 A. No. 14:12 Q. Is there anyone above you at 14:13 all at JUUL? 14:14 A. The CEO. 14:15 Q. And who is that? 14:16 A. K.C. Crosthwaite. | | |
| 48:09 - 48:15 | Murillo, Jose 2021-10-20_WIT | 00:00:19 | MJv6.3 |
| | 48:09 Q. And K.C. Crosthwaite is the 48:10 current -- is he the current CEO of JUUL? 48:11 A. Yes. 48:12 Q. And he was brought over 48:13 probably around a week before you from Altria 48:14 to JUUL, correct? 48:15 A. A week sounds about right. | | |
| 49:04 - 49:20 | Murillo, Jose 2021-10-20_WIT | 00:01:01 | MJv6.4 |
| | 49:04 Q. Do you have an understanding of 49:05 why K.C. Crosthwaite wanted you to come be 49:06 the chief regulatory officer at JUUL? 49:07 A. I do. 49:08 Q. And why is that? 49:09 A. He approached me and said that 49:10 he was in final negotiations to become the 49:11 CEO of JUUL, and should he become the CEO of 49:12 JUUL, he wanted me to consider coming over to 49:13 lead regulatory and external affairs because | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|---------------|--|----------|--------|
| | 49:14 of our prior working relationship, my 49:15 experience in regulatory and external and 49:16 government affairs matters and the fact that 49:17 I had already been supporting JUUL Labs with 49:18 respect to regulatory matters under the 49:19 services agreement between JUUL Labs and 49:20 Altria. | | |
| 57:03 - 57:19 | Murillo, Jose 2021-10-20_WIT | 00:00:55 | MJv6.5 |
| | 57:03 Q. During your time at Altria, 57:04 were you familiar with what was called 57:05 Project Tree? 57:06 A. Yes. 57:07 Q. And what was that? 57:08 A. Project Tree, to my 57:09 recollection, was a code name that was used 57:10 to refer to a possible Altria-JUUL 57:11 transaction. 57:12 Q. And during your time at Altria, 57:13 you were involved with the due diligence 57:14 related to the 35% purchase in JUUL, correct? 57:15 A. Indirectly involved in the 57:16 sense that I was not part of the due 57:17 diligence team, but I helped organize a due 57:18 diligence team and then was privy to at least 57:19 some of their results. | | |
| 59:15 - 59:19 | Murillo, Jose 2021-10-20_WIT | 00:00:13 | MJv6.6 |
| | 59:15 Q. And during your time at Altria, 59:16 Greenleaf did perform some regulatory due 59:17 diligence analysis for the JUUL purchase, 59:18 correct? 59:19 A. Yes. | | |
| 61:02 - 61:10 | Murillo, Jose 2021-10-20_WIT | 00:00:29 | MJv6.7 |
| | 61:02 Q. You also retained Greenleaf 61:03 once you got to JUUL, correct? 61:04 A. I did, yes. 61:05 Q. And why did you do that? 61:06 A. Yeah, I retained Greenleaf to 61:07 help with the JUUL PMTA and sort of JUUL 61:08 regulatory support generally. I thought that 61:09 they could be helpful as we sort of | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|---|----------|---------|
| | 61:10 accelerated our PMTA work. | | |
| 238:07 - 239:04 | Murillo, Jose 2021-10-20_WIT | 00:01:13 | MJv6.8 |
| | 238:07 Q. And were you made aware during 238:08 your time at Altria that the people at 238:09 Greenleaf had -- had concerns that JUUL's 238:10 statements about youth initiation were not 238:11 lining up with its business plans? | | |
| | 238:12 A. I don't recall that, no. I 238:13 recall, as I said, concerns from Greenleaf 238:14 about their relative lack of experience, to 238:15 which I would add, you know, dealing with 238:16 the -- the youth prevention balance that is 238:17 embedded in the Tobacco Control Act through 238:18 the standard that we talked about of 238:19 balancing the benefits and the cons. But I 238:20 don't remember a statement like this. | | |
| | 238:21 Q. Altria retained Greenleaf 238:22 because, in theory, having ex-FDA people and 238:23 things like that, they're experts on 238:24 regulatory matters, correct? | | |
| | 238:25 A. Yes. | | |
| | 239:01 Q. I mean, they -- Altria wouldn't 239:02 have retained them if they didn't bring 239:03 expertise to the table; is that fair? | | |
| | 239:04 A. Yeah. As I said | | |
| 239:08 - 239:10 | Murillo, Jose 2021-10-20_WIT | 00:00:11 | MJv6.9 |
| | 239:08 A. -- I made the recommendation to 239:09 retain Greenleaf. I just don't remember this 239:10 particular statement. | | |
| 245:07 - 245:09 | Murillo, Jose 2021-10-20_WIT | 00:00:06 | MJv6.10 |
| | 245:07 Q. During your time at Altria, you 245:08 knew JUUL had a youth prevention problem, 245:09 right? | | |
| 245:12 - 245:20 | Murillo, Jose 2021-10-20_WIT | 00:00:29 | MJv6.11 |
| | 245:12 A. I don't know what you mean by a 245:13 youth prevention problem, but certainly I 245:14 knew that JUUL products were reported as 245:15 being used by kids in numbers that were high. 245:16 BY MR. DEGREEFF: | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|------------------------|---|----------|---------|
| | 245:17 Q. Use of JUUL product -- high use 245:18 of JUUL product by kids is a problem, 245:19 correct, is it not? 245:20 A. Absolutely. | | |
| 409:19 - 409:19 | Murillo, Jose 2021-10-21_WIT | 00:00:03 | MJv6.12 |
| | 409:19 Q. Okay. Let's do this. We're | | |
| 409:20 - 409:20 | Murillo, Jose 2021-10-21_WIT | 00:00:02 | MJv6.13 |
| | 409:20 going to go to -- let's go to A65. | | |
| 409:25 - 410:01 | Murillo, Jose 2021-10-21_WIT | 00:00:08 | MJv6.14 |
| | 409:25 Q. We'll mark this as the next -- 410:01 as the next exhibit, 50019. | | |
| 412:09 - 412:25 | Murillo, Jose 2021-10-21_WIT | 00:01:06 | MJv6.15 |
| 🔗 MURILLO5001 9.9.1 | 412:09 And so in regard to what's 412:10 actually in the letter itself, is the content 412:11 in the letter something that you were 412:12 familiar with or participated in helping to 412:13 draft? 412:14 A. Yes. 412:15 Q. Okay. All right. So at that 412:16 time in the -- in October of 2018, Altria had 412:17 evaluated the information that was available, 412:18 had looked at the letter that had been sent 412:19 by Commissioner Gottlieb, had had some time 412:20 to evaluate the claims made in Commissioner 412:21 Gottlieb's letter, and had come to the 412:22 conclusion that Altria was concerned about | | |
| 🔗 MURILLO5001 9.9.2 | 412:23 these youth issues and that they were 412:24 concerned that that might jeopardize harm 412:25 reduction for adult smokers, correct? | | |
| 413:01 - 413:01 | Murillo, Jose 2021-10-21_WIT | 00:00:03 | MJv6.16 |
| | 413:01 A. Yeah, I think that's right. | | |
| 413:02 - 414:07 | Murillo, Jose 2021-10-21_WIT | 00:01:18 | MJv6.17 |
| 🔗 MURILLO5001 9.9.3 | 413:02 Q. Okay. And Mr. Willard goes on 413:03 to note: We believe e-vapor products present 413:04 an important opportunity for adult smokers to 413:05 switch from combustible cigarettes. | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|---|----------|---------|
| | 413:06 We've already talked about that 413:07 this morning, correct? 413:08 A. Yes. 🔗 MURILLO5001 413:09 Q. All right. Yet the current 9.9.4 413:10 situation with youth use of e-vapor products, 413:11 left unchecked, has the potential to 413:12 undermine the opportunity for adult smokers. 413:13 Correct? 413:14 A. Yeah, that's what the letter 413:15 says. 413:16 Q. All right. So there was a 413:17 concern by Mr. Willard, and I guess by the 413:18 folks that helped him draft this letter, that 413:19 this youth issue, this youth epidemic, if 413:20 left unchecked, could ruin or undermine or 413:21 limit the ability or opportunity for adult 413:22 smokers to get off combustion cigarettes, 413:23 correct? 413:24 A. Absolutely. 413:25 Q. Okay. And at the time, folks 414:01 at Altria, including you, as you've 414:02 mentioned, as really one of the main focuses 414:03 of your work over the years at Altria, was 414:04 you believed that long-term promise of 🔗 MURILLO5001 9.9.5 414:05 e-vapor products in harm reduction were 414:06 really important for adult smokers, correct? 414:07 A. Absolutely. | | |
| 414:08 - 414:13 | Murillo, Jose 2021-10-21_WIT | 00:00:16 | MJv6.18 |
| | 414:08 Q. Okay. And because of that and 414:09 recognizing that this was a complex 🔗 MURILLO5001 414:10 situation, you were going to have -- Altria 9.9.6 414:11 was going to go ahead and take some immediate 414:12 actions, correct? 414:13 A. Yes. | | |
| 414:14 - 414:21 | Murillo, Jose 2021-10-21_WIT | 00:00:22 | MJv6.19 |
| 🔗 MURILLO5001 | 414:14 Q. All right. And part of that 414:15 was -- if you look at the bottom of the page, | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|--|----------|---------|
| 9.9.7 | 414:15 was -- if you look at the bottom of the page, 414:16 the first arrow point -- that Altria would 414:17 remove from the market our MarkTen Elite and 414:18 Apex by MarkTen pod-based products until we 414:19 receive a market order from the FDA or the 414:20 youth issue is otherwise addressed. Correct? 414:21 A. Yes. | | |
| 415:03 - 415:09 | Murillo, Jose 2021-10-21_WIT | 00:00:24 | MJv6.20 |
| 🔗 MURILLO5001 | 415:03 Q. Okay. And then you went on to | | |
| 9.9.8 | 415:04 also say that you would discontinue the sale 415:05 of all other flavored variants of our 415:06 cig-a-like products until we receive a market 415:07 order from the FDA or the youth issue is 415:08 otherwise addressed. Correct? 415:09 A. That's right. | | |
| 415:10 - 415:17 | Murillo, Jose 2021-10-21_WIT | 00:00:19 | MJv6.21 |
| 🔗 MURILLO5001 | 415:10 Q. And that you would only sell | | |
| 9.9.9 | 415:11 tobacco, menthol and mint varieties, correct? 415:12 A. Yes. | | |
| 🔗 MURILLO5001 | 415:13 Q. Okay. And that Altria would | | |
| 9.9.10 | 415:14 support federal legislation to establish 415:15 21 years old as the minimum age to purchase 415:16 any tobacco product, correct? 415:17 A. Yes. | | |
| 416:09 - 417:01 | Murillo, Jose 2021-10-21_WIT | 00:00:55 | MJv6.22 |
| 🔗 MURILLO5001 | 416:09 Q. As you go down the middle of | | |
| 9.10.1 | | | |
| 🔗 MURILLO5001 | 416:10 page 2, the middle paragraph states: Based | | |
| 9.10.2 | 416:11 on the publicly available information from 416:12 the FDA and others, we believe that pod-based 416:13 products significantly contribute to the rise 416:14 in youth use of e-vapor products. 416:15 Do you see that? | | |
| | 416:16 A. Yes. | | |
| | 416:17 Q. And that was the underlying | | |
| | 416:18 reason why Mr. Willard committed to -- on the | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|----------------------------|---|----------|---------|
| 🔗 MURILLO5001 9.9.7 | 416:19 first page, to removing from the market 416:20 Altria's pod-based products until he received 416:21 a market order from the FDA or the youth 416:22 issue was otherwise addressed, correct? 416:23 A. That's not exactly what the 416:24 letter says. I think he talks about taking 416:25 steps now to preserve long-term opportunity 417:01 in a complex situation. | | |
| 427:16 - 427:21 ☒ Clear | Murillo, Jose 2021-10-21_WIT 427:16 Q. All right. Now, you 427:17 participated in the actual meeting with 427:18 Commissioner Gottlieb, correct, that happened 427:19 earlier that month, in October 2018? 427:20 A. I think it was in October, but 427:21 the meeting that preceded the letter, yes. | 00:00:16 | MJv6.23 |
| 427:23 - 427:25 | Murillo, Jose 2021-10-21_WIT 427:23 And you remember that Howard 427:24 Willard was there, correct? 427:25 A. Yes. | 00:00:05 | MJv6.24 |
| 428:23 - 429:04 | Murillo, Jose 2021-10-21_WIT 428:23 Do you recall -- at the meeting 428:24 with Mr. Willard and Commissioner Gottlieb, 428:25 do you recall specific conversations 429:01 regarding the issues of pod-based products 429:02 being potentially one of the things that has 429:03 driven the rise in youth e-vapor products? 429:04 A. I do. | 00:00:24 | MJv6.25 |
| 429:05 - 429:11 | Murillo, Jose 2021-10-21_WIT 429:05 Q. Do you recall a 429:06 discussion with Commissioner Gottlieb where 429:07 Mr. Willard and him talked about whether or 429:08 not there was enough concern to even consider 429:09 just banning pod-based devices or pod-based 429:10 products until a formal PMTA could be 429:11 granted? | 00:00:22 | MJv6.26 |
| 429:13 - 430:07 | Murillo, Jose 2021-10-21_WIT 429:13 A. My recollection is that we had 429:14 an exchange about a number of things, and | 00:01:21 | MJv6.27 |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|--|----------|---------|
| | <p>429:15 I -- and Mr. Willard led the conversation. I</p> <p>429:16 was part of aspects of the exchange as well.</p> <p>429:17 And what I recall about pods</p> <p>429:18 was in trying to respond to their letter and</p> <p>429:19 our understanding that they wanted ideas as</p> <p>429:20 to what to do, we said, well, we have</p> <p>429:21 reviewed what is available to us and noticed</p> <p>429:22 a few things. And we had -- we made</p> <p>429:23 reference to the public reports, to FDA's own</p> <p>429:24 references to pods, to references to pod</p> <p>429:25 products by public health groups, and at</p> <p>430:01 least one analyst report, as I recall.</p> <p>430:02 And we essentially expressed</p> <p>430:03 the view that ultimately came to the letter,</p> <p>430:04 that we were considering withdrawing our pod</p> <p>430:05 products from the market, which were at their</p> <p>430:06 incipience, and stepping back and coming back</p> <p>430:07 in the context of a PMTA in due course.</p> | | |
| 432:10 - 432:14 | Murillo, Jose 2021-10-21_WIT | 00:00:16 | MJv6.28 |
| 🔗 MURILLO5001 | <p>432:10 Q. So this is actually a</p> <p>9.1.1</p> <p>432:11 letter that came from you, Mr. Murillo,</p> <p>432:12 correct, this March 26th, 2019 letter?</p> <p>432:13 A. These are comments to a docket</p> <p>432:14 that I signed on behalf of Altria.</p> | | |
| 432:15 - 432:20 | Murillo, Jose 2021-10-21_WIT | 00:00:14 | MJv6.29 |
| | <p>432:15 Q. Okay. Would you have</p> <p>432:16 participated in some way in the drafting of</p> <p>432:17 this document?</p> <p>432:18 A. I don't recall vis-`-vis</p> <p>432:19 drafting, but certainly I reviewed and</p> <p>432:20 approved it.</p> | | |
| 436:11 - 437:10 | Murillo, Jose 2021-10-21_WIT | 00:01:16 | MJv6.30 |
| 🔗 MURILLO5001 | <p>436:11 Q. And in this document,</p> <p>9.1.2</p> <p>436:12 Altria Client Services is actually -- at the</p> <p>436:13 bottom of the page, it kind of notes that</p> <p>436:14 when we use the words "we" and "our," we're</p> <p>436:15 referring to ALCS, correct?</p> <p>436:16 A. Right.</p> | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|---|----------|---------|
| | 436:17 Q. Okay. So I just wanted to make 436:18 sure we got our terminology correct. 436:19 If we look at the paragraph 9.1.3 436:20 towards the bottom of the page where it says: 436:21 We also write to provide some context for our 436:22 actions, including purchase of a minority 436:23 interest in JUUL Labs, Incorporated, and to 436:24 urge others to take voluntary steps to 436:25 address youth e-vapor use. Both e-vapor 437:01 manufacturers and the FDA are critical to 437:02 address this problem. 437:03 So at least at this time, in 437:04 March of 2019, there was some understanding 437:05 at Altria Client Services that in order to 437:06 turn this youth e-vapor epidemic around, it 437:07 was going to require some cooperation between 437:08 the e-vapor manufacturers and the FDA, 437:09 correct? 437:10 A. Yes. | | |
| 437:17 - 438:12 | Murillo, Jose 2021-10-21_WIT | 00:00:39 | MJv6.31 |
| 9.2.1 | 437:17 In September 2018, the FDA 437:18 announced that e-cigarette use among youth 437:19 has hit epidemic proportions. We -- that's 437:20 Altria Client Services -- reviewed the 437:21 publicly available data and concluded that, 9.2.2 437:22 1, youth e-vapor use was increasing at a 437:23 concerning rate. 437:24 Correct? 437:25 A. Yes. | | |
| 9.2.3 | 438:01 Q. 2, that pod-based products 438:02 contribute to the problem. Correct? 438:03 A. Yes. | | |
| 9.2.4 | 438:04 Q. That some public health reports 438:05 associate flavors in these products with 438:06 underage use. Correct? | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|---|----------|---------|
| | 438:07 A. Yes. | | |
| 🔗 MURILLO5001 | 438:08 Q. And at the same time, flavors 9.2.5 438:09 play a critical role in migrating adult 438:10 smokers to noncombustible forms of tobacco. 438:11 Correct? 438:12 A. Yes. | | |
| 438:13 - 438:17 | Murillo, Jose 2021-10-21_WIT | 00:00:14 | MJv6.32 |
| 🔗 MURILLO5001 | 438:13 Q. And if you go to the top of the 9.3.1 🔗 MURILLO5001 438:14 next page, the youth e-vapor use issue is 9.3.2 438:15 driven, in large part, by social access. 438:16 Correct? 438:17 A. Yes. | | |
| 438:18 - 439:07 | Murillo, Jose 2021-10-21_WIT | 00:00:38 | MJv6.33 |
| 🔗 MURILLO5001 | 438:18 Q. And the reason I wanted to 9.2.6 438:19 bring this to your attention was this was in 438:20 March 26th of 2019, and this pretty much 438:21 follows what your thoughts were in October of 438:22 2018, correct? 438:23 I mean, it kind of, point by 438:24 point, are the same kind of thoughts Altria 438:25 had in October of 2018, correct? 439:01 A. Yeah, as it relates to that 439:02 paragraph for sure. We go on to talk about a 439:03 lot has happened since October of 2018, 439:04 hopefully in the right direction. But 439:05 absolutely, it tracks our -- the same mindset 439:06 we had at the time of the October letter at 439:07 this time. | | |
| 439:08 - 439:09 | Murillo, Jose 2021-10-21_WIT | 00:00:02 | MJv6.34 |
| 🔗 MURILLO5001 | 439:08 Q. If you go to 9.5.1 439:09 the bottom of page 5, it talks in here, | | |
| 439:10 - 439:25 | Murillo, Jose 2021-10-21_WIT | 00:00:48 | MJv6.35 |
| 🔗 MURILLO5001 | 439:10 Mr. Murillo, of a commitment to include an 9.5.2 | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|---|--|----------|---------|
| | <p>439:11 additional \$100 million investment over two</p> <p>439:12 years in underage tobacco prevention to</p> <p>439:13 specifically address e-vapor use. This</p> <p>439:14 support is in addition to the amount Altria</p> <p>439:15 invests annually in youth tobacco prevention</p> <p>439:16 efforts. We have asked the FDA for guidance</p> <p>439:17 as to how the 100 million may be best spent.</p> <p>439:18 So this is a commitment that --</p> <p>439:19 that Altria decided to make in March of 2019,</p> <p>439:20 above and beyond what they were already</p> <p>439:21 annually investing in youth prevention</p> <p>439:22 efforts?</p> <p>439:23 A. To be precise, the commitment</p> <p>439:24 was announced in February, but we're</p> <p>439:25 reporting it in this letter.</p> | | |
| 440:12 - 440:14 | Murillo, Jose 2021-10-21_WIT | 00:00:04 | MJv6.36 |
| | <p>440:12 This was something Altria</p> <p>440:13 decided to do on their own, correct?</p> <p>440:14 A. Right.</p> | | |
| 440:15 - 440:21 | Murillo, Jose 2021-10-21_WIT | 00:00:15 | MJv6.37 |
| | <p>440:15 Q. All right. And can you tell me</p> <p>440:16 today -- do you have some understanding as to</p> <p>440:17 how this money was spent or where that money</p> <p>440:18 went?</p> <p>440:19 A. I think at least some of it</p> <p>440:20 went to additional access control measures,</p> <p>440:21 but I don't remember beyond that.</p> | | |
| 440:22 - 441:12 | Murillo, Jose 2021-10-21_WIT | 00:00:45 | MJv6.38 |
| <input checked="" type="checkbox"/> Clear | <p>440:22 Q. Is it your understanding that</p> <p>440:23 that investment -- that Altria did invest</p> <p>440:24 that total amount in youth -- in tobacco</p> <p>440:25 prevention efforts? Did they end up spending</p> <p>441:01 all the money or did they just do part of it?</p> <p>441:02 Do you know what happened with that?</p> <p>441:03 A. I don't remember. And I left</p> <p>441:04 before the second part was supposed to be</p> <p>441:05 spent, so I don't know.</p> <p>441:06 Q. Okay. Did you have any</p> <p>441:07 oversight as to how that money was being</p> <p>441:08 spent, or was that some other department?</p> | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|---|----------|---------|
| | 441:09 A. I may have been part of -- I'm 441:10 sure I was part of conversations as to how it 441:11 could be spent, but I was not responsible 441:12 directly for how the money was spent. | | |
| 462:19 - 462:22 | Murillo, Jose 2021-10-21_WIT | 00:00:10 | MJv6.39 |
| | 462:19 But were you the one that 462:20 initially brought Greenleaf in to work on the 462:21 Project Tree issue? 462:22 A. Yes. | | |
| 464:05 - 464:08 | Murillo, Jose 2021-10-21_WIT | 00:00:12 | MJv6.40 |
| | 464:05 MR. BLAudeau: And there's a 464:06 Bates stamp on this document as well 464:07 that we can reference, 464:08 ALGAT0004584798. | | |
| 464:25 - 465:04 | Murillo, Jose 2021-10-21_WIT | 00:00:12 | MJv6.41 |
| 🔗 MURILLO5002 | 464:25 Q. So this is a -- this is the 0.1.1 465:01 team from Greenleaf Health that was assigned 465:02 to Project Tree, correct? 465:03 A. For Altria and the diligence 465:04 team, yes. | | |
| 465:05 - 465:13 | Murillo, Jose 2021-10-21_WIT | 00:00:23 | MJv6.42 |
| | 465:05 Q. Yes. And -- 465:06 A. I'm sorry, that's what the 465:07 document said. I think I -- I have no 465:08 independent recollection of what the team 465:09 was, as I've mentioned now several times. I 465:10 retained them, I directed them through the 465:11 overall diligence team, and then I exited 465:12 because I did not want to be part of the 465:13 clean team. | | |
| 465:14 - 465:21 | Murillo, Jose 2021-10-21_WIT | 00:00:16 | MJv6.43 |
| | 465:14 Q. And the only 465:15 reason I bring this up is because the ladies 465:16 and gentlemen of the jury may not really 465:17 understand what this entity does or how they 465:18 interact, and I just wanted to get some 465:19 context in about them. | | |
| 🔗 MURILLO5002 | 465:20 So there's a core team here | | |

MJv6 - MURILLO, JOSE SFUSD FINAL_PLAYED 05-04-23

| DESIGNATION | SOURCE | DURATION | ID |
|-----------------|--|----------|---------|
| 0.1.2 | 465:20 So there's a core team here 465:21 that lists several people. | | |
| 466:10 - 466:18 | Murillo, Jose 2021-10-21_WIT | 00:00:27 | MJv6.44 |
| 🔗 MURILLO5002 | 466:10 Q. So in looking through the | | |
| 0.8.1 | | | |
| 🔗 MURILLO5002 | 466:11 Greenleaf personnel, it seemed like a lot of 466:12 these folks had some significant ties, one | | |
| 0.9.1 | | | |
| 🔗 MURILLO5002 | 466:13 way or another, with the FDA. 466:14 Is that your understanding as | | |
| 0.10.1 | | | |
| 🔗 MURILLO5002 | 466:15 well, sir? 466:16 A. You said some of these folks? | | |
| 0.11.1 | | | |
| 🔗 MURILLO5002 | 466:17 Q. Yeah. Yeah. | | |
| 0.12.1 | | | |
| | 466:18 A. Yes. That's right. | | |
| 582:19 - 582:20 | Murillo, Jose 2021-10-21_WIT | 00:00:03 | MJv6.45 |
| ☒ Clear | 582:19 MR. BLAUDEAU: Thank you, sir. 582:20 That's all I have. I appreciate it. | | |

| | |
|-----------------------|-----------------|
| PLF AFFIRMATIVE | 00:11:02 |
| DEF COUNTER | 00:06:10 |
| PLF COUNTER-COUNTER | 00:02:33 |
| TOTAL RUN TIME | 00:19:46 |



Documents linked to video:
 MURILLO50019
 MURILLO50020

EXHIBIT 2

[Submitting Counsel on Signature Page]

UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
SAN FRANCISCO DIVISION

IN RE JUUL LABS, INC.,
MARKETING, SALES PRACTICES,
AND PRODUCTS LIABILITY
LITIGATION

Case No. 19-md-02913-WHO

JOINT STIPULATION IDENTIFYING
TRIAL EXHIBITS USED IN THE
VIDEOTAPED DEPOSITION OF JOSE
MURILLO PLAYED AT TRIAL

This Document Relates to:

*San Francisco Unified School District v.
Juul Labs, Inc. et al.*, Case No. 3:19-cv-
08177

WHEREAS, Plaintiff called Jose Murillo, whose videotaped deposition was played to the jury.

WHEREAS, the exhibit numbers in the videotaped deposition are different from the Trial Exhibit numbers.

WHEREAS, to most efficiently clarify the record, the parties, by and through their undersigned counsel, hereby stipulate and agree that the chart below accurately reflects the deposition exhibits introduced during the videotaped testimony of Jose Murillo and the corresponding Trial Exhibit Numbers¹:

¹ The parties reserve all objections regarding these exhibits.

| DEPOSITION EXHIBIT NUMBER | TRIAL EXHIBIT NUMBER |
|---------------------------|----------------------|
| Murillo Exhibit 50019 | Trial Exhibit 3303 |
| Murillo Exhibit 50020 | Trial Exhibit 3359 |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

1
2
3 By: /s/ Beth A. Wilkinson
Beth A. Wilkinson (pro hac vice)
4 Brian L. Stekloff (pro hac vice)
James M. Rosenthal (pro hac vice)
5 Matthew R. Skanchy (pro hac vice)
Alysha Bohanon (pro hac vice)
6 WILKINSON STEKLOFF LLP
2001 M Street NW, 10th Floor
Washington, DC 20036
7 Telephone: (202) 847-4000
bwilkinson@wilkinsonstekloff.com
bstekloff@wilkinsonstekloff.com
jrosenthal@wilkinsonstekloff.com
mskanchy@wilkinsonstekloff.com
abohanon@wilkinsonstekloff.com

8
9
10 Moira K. Penza (pro hac vice)
11 WILKINSON STEKLOFF LLP
130 West 42nd Street, 24th Floor
New York, NY 10036
Telephone: 212-294-8910
mpenza@wilkinsonstekloff.com

12
13 By: /s/ John C. Massaro
14 ARNOLD & PORTER KAYE
SCHOLER LLP
John C. Massaro (admitted pro hac vice)
David E. Kouba (admitted pro hac vice)
601 Massachusetts Ave., N.W.
Washington D.C. 20001
Telephone: (202) 942-5000
Facsimile: (202) 942-5999
john.massaro@arnoldporter.com
david.kouba@arnoldporter.com

15
16
17
18
19
20
21
22 Attorneys for Defendants ALTRIA
GROUP, INC., PHILIP MORRIS USA
INC., ALTRIA CLIENT SERVICES LLC,
ALTRIA GROUP DISTRIBUTION
COMPANY, and ALTRIA
ENTERPRISES LLC

23
24
25
26
27 Respectfully submitted,

28
3 By: /s/ Michael M. Weinkowitz
Michael M. Weinkowitz
LEVIN SEDRAN & BERMAN, LLP
510 Walnut Street
Suite 500
Philadelphia PA 19106
Telephone 215-592-1500
MWeinkowitz@lfsblaw.com
Plaintiff Steering Committee Member

4
5 Sarah R. London
Sarah R. London
LIEFF CABRASER HEIMANN & BERNSTEIN
275 Battery Street, Fl. 29
San Francisco, CA 94111
Telephone: (415) 956-1000
slondon@lchb.com

6
7 By: /s/ Dena C. Sharp
Dena C. Sharp
GIRARD SHARP LLP
601 California St., Suite 1400
San Francisco, CA 94108
Telephone: (415) 981-4800
dsharp@girardsharp.com

8
9 By: /s/ Dean Kawamoto
Dean Kawamoto
KELLER ROHRBACK L.L.P.
1201 Third Ave., Ste. 3200
Seattle, WA 98101
Telephone: (206) 623-1900

10
11
12
13 By: /s/ Ellen Relkin
Ellen Relkin
WEITZ & LUXENBERG
700 Broadway
New York, NY 10003
Telephone: (212) 558-5500
Co-Lead Counsel for Plaintiff